leadf
logo-loader
viewOrthocell Ltd

Orthocell's Paul Anderson hails 'fantastic outcome' in CelGro nerve repair study

Orthocell Ltd's (ASX:OCC) Paul Anderson speaks to Proactive's Andrew Scott soon after announcing positive long-term clinical data for its CelGro® nerve repair study. The regenerative medicine company has decided that the clinical results have met the study objectives and has now closed recruitment. They're progressing regulatory applications in Australia and will start the US regulatory study shortly.

Quick facts: Orthocell Ltd

Price: 0.525 AUD

ASX:OCC
Market: ASX
Market Cap: $99.12 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Orthocell Ltd named herein, including the promotion by the Company of Orthocell Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Orthocell Ltd secures new US divisional patent for CelGro®

Orthocell Ltd's (ASX:OCC) Paul Anderson talks Proactive's Andrew Scott through a new US divisional patent they've secured for CelGro® that covers the method of manufacture of collagen medical devices and as an aid in the surgical repair of soft tissue injuries. Orthocell has already been granted...

1 week, 5 days ago

2 min read